We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Leptospira IgM ELISA Evaluated Among Outpatients in Southern Asia

By LabMedica International staff writers
Posted on 26 May 2021
Print article
Image: The Leptospira ELISA IgM assay (Photo courtesy of Panbio)
Image: The Leptospira ELISA IgM assay (Photo courtesy of Panbio)
Leptospirosis is a widespread but neglected zoonotic disease caused by a bacterium of the genus Leptospira. Leptospirosis contributes to approximately 48,000 annual deaths globally, with 500,000 cases estimated worldwide, and remains a major public health concern in tropical and subtropical regions. Weil’s disease is a severe form of leptospirosis.

The serological “gold standard” for identifying pathogenic Leptospira is the microscopic agglutination test (MAT); however, it requires significant technical expertise and the maintenance of viable Leptospira serovars. Microscopic agglutination test is often not beneficial for acute patient management, mainly because it relies on immunoglobulins which react five days after the exposure.

Tropical Medicine specialists at Mahidol University (Salaya, Thailand) and their international colleagues evaluated a Leptospira ELISA IgM assay among 656 febrile outpatients attending primary care in Chiangrai, Thailand, and Hlaing Tha Yar, Yangon, Myanmar. Inclusion criterion was a documented fever (tympanic temperature > 37.5°C) or a complaint of acute fever (< 14 days). Of primary care children and adults recruited in the original trial, 799 were randomized in a control group for whom various samples were collected. From these 799 outpatients, 740 had a blood sample collected.

A commercial Leptospira ELISA IgM assay (Panbio Pty., Ltd., Windsor, Australia) was used for the detection of IgM antibodies against Leptospira spp. The manufacturer’s specifications were followed with Panbio units of ≥ 11.0 considered positive. Positive Leptospira IgM ELISA samples were then tested by MAT, with titers of ≥ 1:100 used to classify past exposure to leptospirosis. TaqMan Array Card (TAC) and single-plex PCR assays were performed on 601 blood samples where sufficient plasma volumes were able to be extracted. The TAC assay targeted all pathogenic serovars of the Leptospira genus, whereas the single-plex PCR used real-time methodology to target the rss gene.

The team reported that the ELISA demonstrated limited diagnostic accuracy for the detection of acute leptospiral infection using the manufacturer recommended cutoff, with a sensitivity of 71.4% and specificity of 36.4%, and an area under the receiver operator characteristic curve value of 0.65, compared with the reference test, the PCR assay. ELISA also performed poorly as a screening tool for detecting recent exposure to Leptospira spp. compared with the “gold-standard” MAT, with a specificity of 42.7%. The proportion of patients with a confirmed acute leptospirosis infection as defined by either single-plex or TAC PCR assay was 1.1% (7/656), whereas 23.5% (154/656) were seropositive by IgM ELISA.

The authors concluded that the IgM ELISA, although simple and widely used, was found to be unsuitable for detecting acute leptospirosis infection among outpatient children and adults attending primary care, using PCR assays as a reference method Even so, it is unlikely that such test, used on an acute sample, may represent an attractive candidate for the diagnosis of acute leptospirosis. The IgM ELISA was not specific as a screening method for recent exposure to pathogenic Leptospira. Using the MAT, the scientists demonstrated a significant exposure (30.5%) to pathogenic Leptospira among Thai and Myanmar communities, including rural and semi-urban settings. The study was published on May 5, 2021 in The American Journal of Tropical Medicine and Hygiene.

Related Links:
Mahidol University
Panbio Pty., Ltd



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.